eFFECTOR Therapeutics Garners $16,000,000 Series B Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=795045c1-3b1a-4d0f-ad3a-f66d9dfc0747 - Date
2/19/2016 - Company Name
eFFECTOR Therapeutics - Mailing Address
11180 Roselle Street San Diego, CA 92121 USA - Company Description
eFFECTOR Therapeutics is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention. - Website
http://www.effector.com - Transaction Type
Venture Equity - Transaction Amount
$16,000,000 - Transaction Round
Series B - Proceeds Purposes
These developments further position eFFECTOR to pursue comprehensive clinical development of its lead product candidate, eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, across multiple tumor types. The funds will also be used to advance the company’s discovery pipeline addressing additional targets. - M&A Terms
- Venture Investor
Sectoral Asset Management - Venture Investor
Undisclosed
